CLAIMS

1. A compound represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof, wherein:

Q is:

1) $R^{10}OC(=O)$-;

2) a heteroaryl ring optionally substituted with 1 to 3 groups independently selected from R^{21};

3) a group of formula R^{30}-L, wherein R^{30} is optionally substituted with 1 to 3 groups independently selected from R^{31}; or

4) a group of formula R^{40}-L, wherein R^{40} is optionally substituted with 1 to 3 groups independently selected from R^{41};

R^1 is selected from $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, $(C_3\text{-}C_6)$cycloalkylalkyl$(C_1\text{-}C_3)$alkyl, aryl$(C_1\text{-}C_3)$alkyl, halo$(C_1\text{-}C_6)$alkyl, halo$(C_3\text{-}C_6)$cycloalkyl, halo$(C_3\text{-}C_6)$cycloalkyl$(C_1\text{-}C_3)$alkyl, amino, $(C_1\text{-}C_6)$alkylamino, di$(C_1\text{-}C_6)$alkylamino, aryl$(C_1\text{-}C_3)$alkylamino and {aryl$(C_1\text{-}C_3)$alkyl}{$(C_1\text{-}C_6)$ alkyl}amino, wherein the aryl groups are optionally substituted with 1 to 3 groups independently selected from halogen, cyano, $CONH_2$, $(C_1\text{-}C_3)$alkyl, halo$(C_1\text{-}C_3)$alkyl, $(C_1\text{-}C_3)$alkoxy and halo$(C_1\text{-}C_3)$alkoxy;

R^2 is selected from hydrogen, halogen, cyano, $CONH_2$, hydroxy$(C_1\text{-}C_3)$alkyl, amino$(C_1\text{-}C_3)$alkyl, $(C_1\text{-}C_3)$alkoxy$(C_1\text{-}C_3)$alkyl, $(C_1\text{-}C_3)$alkylcarbonyl$(C_1\text{-}C_3)$alkyl and $(C_1\text{-}C_3)$alkylcarbonylamino$(C_1\text{-}C_3)$alkyl; or R^2 is a 5-membered heteroaryl, optionally substituted with 1 or 2 groups independently selected from halogen, cyano, methyl, CF_3, methoxy, methoxycarbonyl, ethoxycarbonyl and $CONH_2$;

R^3 is (1) $(C_1\text{-}C_6)$alkyl, halo$(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, halo$(C_3\text{-}C_6)$cycloalkyl, $(C_1\text{-}C_3)$alkoxy$(C_1\text{-}C_3)$alkyl, hydroxy$(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxycarbonyl or $(C_1\text{-}C_6)$alkoxycarbonyl$(C_1\text{-}C_3)$alkyl, or cyano$(C_1\text{-}C_6)$alkyl; or (2) aryl, heteroaryl, aryl$(C_1\text{-}C_3)$alkyl or

heteroaryl(C_1-C_3)alkyl, each optionally substituted with 1 to 3 substituents selected from halogen, cyano, (C_1-C_3)alkyl, CF_3, methoxy and $CONH_2$;

R^4 is hydrogen or (C_1-C_6)alkyl;

R^{10} is selected from (C_1-C_8)alkyl, aryl(C_1-C_3)alkyl, halo(C_1-C_6)alkyl, (C_3-C_7)cycloalkyl, (C_3-C_6)cycloalkyl(C_1-C_3)alkyl, halo(C_3-C_7)cycloalkyl and halo(C_3-C_6)cycloalkyl(C_1-C_3)alkyl;

R^{30} is an aryl or a monocyclic 5- or 6-membered heteroaromatic radical containing 1-4 heteroatoms independently selected from N, O, and S;

R^{40} is (C_4-C_7)cycloalkyl or heterocyclyl;

R^{21}, R^{31}, and R^{41} are each independently selected from halogen, hydroxy, amino, nitro, (C_1-C_6)alkyl, halo(C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_2-C_6)alkenyl, (C_1-C_6)alkoxy, halo(C_1-C_6)alkoxy, hydroxy(C_1-C_6)alkyl, hydroxy(C_1-C_6)haloalkyl, (C_1-C_3)alkoxy(C_1-C_3)alkyl, halo(C_1-C_3)alkoxy(C_1-C_3)alkyl, (C_1-C_3)alkoxy(C_1-C_3)haloalkyl, (C_1-C_6)alkylthio, halo(C_1-C_6)alkylthio, (C_1-C_3)alkylthio(C_1-C_3)alkyl, halo(C_1-C_3)alkylthio(C_1-C_3)alkyl, cyano(C_1-C_6)alkyl, CO_2H, (C_1-C_6)alkoxycarbonyl, (C_1-C_6)alkylsulfonyl, (C_1-C_6)haloalkylsulfonyl, (C_1-C_3)alkylsulfonyl(C_1-C_3)alkyl, halo(C_1-C_3)alkylsulfonyl(C_1-C_3)alkyl, heterocyclyl, $R^{22}R^{23}NCO$, $R^{22}R^{23}NCO$(C_1-C_3)alkyl, $R^{22}CONH$, $R^{22}CONH$(C_1-C_3)alkyl, $R^{22}SO_2NH$, $R^{22}SO_2NH$(C_1-C_3)alkyl, $R^{22}R^{23}N$, $R^{22}R^{23}N$(C_1-C_3)alkyl and aryl(C_1-C_3)alkyl, wherein aryl(C_1-C_3)alkyl is optionally substituted by R^{25};

R^{22} is selected from H, (C_1-C_6)alkyl, halo(C_1-C_6)alkyl, hydroxy(C_1-C_6)alkyl, (C_1-C_6)alkoxy(C_1-C_6)alkyl, (C_1-C_6)alkoxycarbonyl(C_1-C_6)alkyl, (C_1-C_6)alkoxycarbonylamino(C_1-C_6)alkyl and heterocyclyl, wherein the heterocyclyl is optionally substituted with 1 or 2 groups independently selected from R^{24};

R^{23} is hydrogen, (C_1-C_6)alkyl, (C_1-C_6)alkoxy or halo(C_1-C_6)alkyl; or R^{22} and R^{23}, together with the nitrogen to which they are attached, form an azetidine, pyrrolidine, piperidine, piperazine or morpholine ring, each optionally substituted by 1 or 2 groups independently selected from R^{24};

R^{24} is selected from halogen, hydroxy, amino (C_1-C_3)alkyl, halo(C_1-C_3)alkyl, (C_1-C_3)alkoxy and (C_1-C_6)alkoxycarbonyl;

R^{25} is hydroxy(C_1-C_6)alkyl or CO_2H;

L is CH_2, $CHCH_3$ or $C(CH_3)_2$; and

Y is hydrogen, halogen, cyano, (C_1-C_3)alkyl, methyl, haloalkyl, or methoxy.

2. The compound of Claim 1, wherein

Q is

1) $R^{10}OC(=O)$-;

2) 2-pyridyl, 3-pyridyl, 4-pyridyl, 3-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 2-pyrazinyl, 2-oxazolyl, 2-thiazolyl, 1,3,4-thiadiazol-2-yl, 2-pyridon-4-yl, 2-benzoxazolyl, 2-benzothiazolyl, thiazolo[4,5-b]pyridin-2-yl, thiazolo[4,5-c]pyridin-2-yl, thiazolo[5,4-c]pyridin-2-yl or thiazolo[5,4-b]pyridin-2-yl, each optionally substituted by one to three groups independently selected from R^{21};

3) phenylCH_2, phenylCHMe, pyridylCH_2, furanylCH_2, each optionally substituted with one to three substituents independently selected from R^{31}; or

4) cyclohexylCH_2, bicyclo[3.1.0]hexylCH_2, spiro[2.5]octylCH_2, piperidinylCH_2, pyrrolidinylCH_2 and tetrahydropyranylCH_2, each optionally substituted with one to three substituents independently selected from R^{41};

R^1 is selected from Me, -NH_2, -NHMe, and -NMe-4-methoxybenzyl;

R^2 is selected from (1) H, F, Cl, CN, CF_3, CH_2OH, CH_2NH_2, $CONH_2$, CH_2OAc, CH_2OMe, and CH_2NHAc or (2) 2-oxazolyl, 1,3,4-oxadiazol-2-yl, 1,2,4-oxadiazol-5-yl, 2-thiazolyl and 1,3,4-thiadiazol-2-yl each of which is optionally substituted with a group selected from methyl, cyano, ethoxycarbonyl and $CONH_2$;

Y is H, F or Cl;

R^3 is selected from i-Pr, i-Bu, t-Bu, CF_3, CF_2Me, CH_2CMe_2F, CH_2CF_3, CH(OMe)Me, c-Pr, c-hexyl, phenyl, 2-Cl-phenyl, 2-Br-phenyl, 2-Me-phenyl, 3-Cl-phenyl, 3-Me-phenyl, 4-F-phenyl, 4-Cl-phenyl, 4-Br-phenyl, benzyl, 4-methyl-2-thiazolyl, CO_2Me, CMe_2OH and CH_2CMe_2OH;

R^4 is H or methyl;

R^{10} is selected from i-Pr, t-Bu, i-Bu, t-BuCH_2, benzyl, CF_3CH_2, CF_3CHMe, CF_3CMe_2, and 2,2,3,3-tetrafluorocyclobutyl;

R^{21} is selected from F, Cl, Br, CN, NO_2, NH_2, OH, Me, i-Pr, c-Pr, $C(=CH_2)Me$, CHF_2, CF_3, CF_2Me, OMe, Oi-Pr, $OCHF_2$, OCH_2CF_3, CH_2OH, CH(OH)Me, CH(OH)Et, $CH(OH)CF_3$, CMe_2OH, $CMe(OH)CF_3$, $CH(OMe)CF_3$, CMe_2CN, C(=O)H, C(=O)Me, SO_2Me, CO_2H, CO_2Me,

CO_2Et, $CONR^{22}R^{23}$, $CH_2NR^{22}R^{23}$, CH_2NHAc, CH_2SMe, CH_2NHSO_2Me, $CH_2C_6H_4R^{25}$ and 4,4-dimethyl-2-oxazolidinyl;

R^{22} is selected from H, Me, Et, n-Bu, t-Bu, CH_2CH_2OH, CH_2CH_2OMe, $CH_2CH_2CH_2OH$, $CH_2CH_2CMe_2OH$, $CH_2CH_2CH_2OMe$, CH_2CO_2Et, $CH_2CH_2CO_2Et$; $CH_2CH_2CH_2NHCO_2Me$, $CH_2CH_2CH_2NHCO_2t$-Bu, and N-t-BuOC(=O)-3-azetidinyl;

R^{23} is hydrogen, methyl, ethyl or methoxy; or R^{22} and R^{23}, together with the nitrogen to which they are attached, form an azetidine or morpholine ring, each optionally substituted by one or two groups independently selected from R^{24};

R^{24} is F, OH, OMe, or NH_2;

R^{25} is CO_2H or CMe_2OH;

R^{31} is selected from F, Cl, Br, Me, i-Pr, CF_3, $OCHF_2$, OCF_3, $CMe(OH)CF_3$, CO_2Me and CMe_2OH; and

R^{41} is selected from F, OH, OMe, Me, i-Pr, CHF_2, CF_3, CH_2CF_3, CF_2CH_3, and CMe_2OH.

3. The compound of Claim 1, wherein

Q is pyridyl or pyrimidinyl, each being substituted with one or two groups independently selected from R^{21};

R^1 is selected from methyl, NH_2 and NHMe;

R^2 is H, F or CH_2OH; Y is H;

R^3 is i-Pr; and

R^4 is H.

4. The compound of Claim 1, wherein

Q is 2-pyridyl or 2-pyrimidinyl, each being substituted with one CF_3 group and optionally substituted with a second group selected from R^{21}; and

R^1 is methyl.

5. The compound of Claim 1, wherein at least one R^{21} is a hydroxy(C_1-C_4)alkyl group.

6. The compound of Claim 1, wherein

Q is phenylCH_2 or pyridylCH_2, each being optionally substituted with one to three substituents independently selected from R^{31};

R^1 is methyl, NH_2 or NHMe;

R^2 is H, F or CH_2OH;

Y is H;

R^3 is selected from i-Pr, phenyl and halophenyl; and

R^4 is H.

7. The compound of Claim 1, wherein

Q is phenylCH_2 or 3-pyridylCH_2, each being substituted with one CF_3 group and optionally substituted with one other group selected from R^{31};

R^1 is methyl; and

R^3 is isopropyl.

8. The compound of Claim 1, wherein

Q is cyclohexylCH_2, piperidinylCH_2 or tetrahydropyranylCH_2, each being optionally substituted with one to three substituents independently selected from R^{41};

R^1 is methyl, NH_2 or NHMe;

R^2 is H, F or CH_2OH;

Y is H;

R^3 is isopropyl, phenyl or halophenyl; and

R^4 is H.

9. The compound of Claim 1, wherein

Q is cyclohexylCH_2, 3-piperidinylCH_2, or 3-tetrahydropyranylCH_2, each being substituted with one CF_3 group and optionally substituted with one other group selected from R^{41};

R^1 is methyl; and

R^3 is isopropyl.

10. The compound of Claim 1, wherein the compound is of the Formula Ia or Ib:



Ia



Ib ;

or a pharmaceutically acceptable salt thereof.

11. The compound of Claim 1, wherein the compound is represented by structural Formula Ic or Id:



Ic



Id

or a pharmaceutically acceptable salt thereof, wherein m is 1, 2 or 3.

12. The compound of Claim 1, wherein the compound is represented by structural Formula Ik:



Ik ;

or a pharmaceutically acceptable salt thereof, wherein n is 0, 1 or 2; and A is CH_2, NH, NMe or O.

13. A pharmaceutical composition comprising a pharmaceutical carrier or diluent and the compound of Claim 1, or a pharmaceutically acceptable salt thereof.

14. The compound of Claim 1, wherein the compound is represented by structural Formula Ie or If:



Ie



If ;

or a pharmaceutically acceptable salt thereof.

15. The compound of Claim 1, wherein the compound is represented by structural Formula Ig:



Ig ;

or a pharmaceutically acceptable salt thereof, wherein m is 1, 2 or 3.

16. The compound of Claim 1, wherein the compound is represented by structural Formula Ih:



Ih ;

or a pharmaceutically acceptable salt thereof, wherein m is 1, 2 or 3.

17. The compound of Claim 1, wherein the compound is represented by structural Formula Ii:



Ii ;

or a pharmaceutically acceptable salt thereof, wherein m is 1, 2 or 3.

18. The compound of Claim 1, wherein the compound is represented by structural Formula Ij:



Ij ;

or a pharmaceutically acceptable salt thereof.

19. The compound of Claim 1, wherein the compound is represented by structural Formula Il:



Il ;

or a pharmaceutically acceptable salt thereof, wherein n is 0, 1 or 2; and A is CH_2, NH, NMe or O.

20. The compound of Claim 1, wherein the compound is represented by structural Formula Im:



Im ;

or a pharmaceutically acceptable salt thereof, wherein A is CH_2, NH, NMe or O.

21. The compound of Claim 1, wherein the compound is represented by structural Formula In:



In ;

or a pharmaceutically acceptable salt thereof, wherein A is CH_2, NH, NMe or O.

22. The compound of Claim 1, wherein the compound is represented by structural Formula Io:



Io ;

or a pharmaceutically acceptable salt thereof, wherein A is CH_2, NH, NMe or O.

23. The compound of Claim 1, wherein the compound is represented by structural Formula Ip:



Ip ;

or a pharmaceutically acceptable salt thereof.